5.95
price down icon11.85%   -0.80
 
loading
Omeros Corporation stock is traded at $5.95, with a volume of 1.37M. It is down -11.85% in the last 24 hours and up +43.37% over the past month. Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$6.75
Open:
$6.75
24h Volume:
1.37M
Relative Volume:
2.79
Market Cap:
$374.92M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
9.2969
EPS:
0.64
Net Cash Flow:
$74.30M
1W Performance:
+38.69%
1M Performance:
+43.37%
6M Performance:
+72.46%
1Y Performance:
+262.80%
1-Day Range:
Value
$5.82
$6.75
1-Week Range:
Value
$4.175
$7.51
52-Week Range:
Value
$1.60
$7.51

Omeros Corporation Stock (OMER) Company Profile

Name
Name
Omeros Corporation
Name
Phone
206-676-5000
Name
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Name
Employee
198
Name
Twitter
@OmerosCorp
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
OMER's Discussions on Twitter

Compare OMER with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
OMER 5.95 374.92M 0 -117.81M 74.30M 0.64
VRTX 467.79 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.02 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.78 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.65 24.08B 3.30B -501.07M 1.03B 11.54

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-08-22 Downgrade UBS Buy → Neutral
Nov-08-22 Downgrade BofA Securities Neutral → Underperform
Jun-08-22 Downgrade BofA Securities Buy → Neutral
Oct-08-21 Downgrade JP Morgan Neutral → Underweight
Oct-01-21 Downgrade Maxim Group Buy → Hold
Oct-01-21 Downgrade Wedbush Neutral → Underperform
Sep-27-21 Initiated JP Morgan Neutral
Feb-01-21 Initiated UBS Buy
Oct-20-20 Initiated BofA Securities Buy
Aug-21-20 Reiterated H.C. Wainwright Buy
Aug-14-20 Reiterated Maxim Group Buy
May-06-19 Initiated Cantor Fitzgerald Overweight
Jul-12-18 Initiated Seaport Global Securities Buy
Mar-23-18 Downgrade Wedbush Outperform → Neutral
Mar-05-18 Downgrade Needham Buy → Hold
Nov-08-17 Initiated H.C. Wainwright Buy
May-11-17 Downgrade Cantor Fitzgerald Buy → Neutral
Mar-17-17 Reiterated Maxim Group Buy
Mar-17-17 Reiterated Needham Buy
Nov-16-16 Reiterated Wedbush Outperform
Nov-10-16 Reiterated Needham Buy
Aug-10-16 Reiterated Maxim Group Buy
Jun-03-16 Initiated Cantor Fitzgerald Buy
Mar-02-16 Reiterated Needham Buy
Feb-29-16 Reiterated Wedbush Outperform
Nov-11-15 Reiterated Needham Buy
Aug-18-15 Reiterated WBB Securities Strong Buy
Aug-10-15 Initiated ROTH Capital Buy
View All

Omeros Corporation Stock (OMER) Latest News

pulisher
Nov 17, 2024

Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha

Nov 17, 2024
pulisher
Nov 16, 2024

Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News

Nov 15, 2024
pulisher
Nov 15, 2024

Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN

Nov 14, 2024
pulisher
Nov 14, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros stock soars to 52-week high, hits $5.68 - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros initiated with a Buy at Rodman & Renshaw - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros: Q3 Earnings Snapshot - New Haven Register

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros up 4% as Q3 results beat on EPS - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Corporation Reports Third Quarter 2024 Financial Results - The Bakersfield Californian

Nov 13, 2024
pulisher
Nov 13, 2024

Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Earnings Outlook For Omeros - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Omeros (OMER) Scheduled to Post Earnings on Wednesday - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Omeros (OMER) Sets Q3 2024 Earnings Call for November 13: What to Watch | OMER Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews

Nov 11, 2024
pulisher
Nov 06, 2024

Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat

Nov 06, 2024
pulisher
Oct 31, 2024

Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online

Oct 31, 2024
pulisher
Oct 29, 2024

Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Focal Segmental Glomerulosclerosis Drugs Market Report 2024FSGS Drugs Market Size - WhaTech

Oct 28, 2024
pulisher
Oct 25, 2024

Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com

Oct 25, 2024
pulisher
Oct 25, 2024

Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - Pharmacy Times

Oct 25, 2024
pulisher
Oct 24, 2024

OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire

Oct 24, 2024
pulisher
Oct 22, 2024

Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com

Oct 22, 2024
pulisher
Oct 22, 2024

Omer Riza wants 'clarity' over Cardiff City manager position exactly one month on from Bulut sacking - Wales Online

Oct 22, 2024
pulisher
Oct 21, 2024

Ischemia Reperfusion Injury Therapeutics Market Generated - openPR

Oct 21, 2024
pulisher
Oct 21, 2024

Next Cardiff City manager latest as Omer Riza now favourite for job - Wales Online

Oct 21, 2024
pulisher
Oct 17, 2024

Omer Arbel Office unveils planned community for Washington State site - The Architect's Newspaper

Oct 17, 2024
pulisher
Oct 17, 2024

OMER (Omeros) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Omeros Corporation Stock (OMER) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):